Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

Validation of an algorithm for identifying MS cases in administrative health claims datasets.

Culpepper WJ, Marrie RA, Langer-Gould A, Wallin MT, Campbell JD, Nelson LM, Kaye WE, Wagner L, Tremlett H, Chen LH, Leung S, Evans C, Yao S, LaRocca NG; United States Multiple Sclerosis Prevalence Workgroup (MSPWG).

Neurology. 2019 Mar 5;92(10):e1016-e1028. doi: 10.1212/WNL.0000000000007043. Epub 2019 Feb 15.

2.

The prevalence of MS in the United States: A population-based estimate using health claims data.

Wallin MT, Culpepper WJ, Campbell JD, Nelson LM, Langer-Gould A, Marrie RA, Cutter GR, Kaye WE, Wagner L, Tremlett H, Buka SL, Dilokthornsakul P, Topol B, Chen LH, LaRocca NG; US Multiple Sclerosis Prevalence Workgroup.

Neurology. 2019 Mar 5;92(10):e1029-e1040. doi: 10.1212/WNL.0000000000007035. Epub 2019 Feb 15.

3.

A new way to estimate neurologic disease prevalence in the United States: Illustrated with MS.

Nelson LM, Wallin MT, Marrie RA, Culpepper WJ, Langer-Gould A, Campbell J, Buka S, Tremlett H, Cutter G, Kaye W, Wagner L, Larocca NG; United States Multiple Sclerosis Prevalence Workgroup.

Neurology. 2019 Mar 5;92(10):469-480. doi: 10.1212/WNL.0000000000007044. Epub 2019 Feb 15. Review.

4.

Validation of the Swedish Multiple Sclerosis Register: Further Improving a Resource for Pharmacoepidemiologic Evaluations.

Alping P, Piehl F, Langer-Gould A, Frisell T; COMBAT-MS Study Group.

Epidemiology. 2019 Mar;30(2):230-233. doi: 10.1097/EDE.0000000000000948.

5.

Admixture mapping reveals evidence of differential multiple sclerosis risk by genetic ancestry.

Chi C, Shao X, Rhead B, Gonzales E, Smith JB, Xiang AH, Graves J, Waldman A, Lotze T, Schreiner T, Weinstock-Guttman B, Aaen G, Tillema JM, Ness J, Candee M, Krupp L, Gorman M, Benson L, Chitnis T, Mar S, Belman A, Casper TC, Rose J, Moodley M, Rensel M, Rodriguez M, Greenberg B, Kahn L, Rubin J, Schaefer C, Waubant E, Langer-Gould A, Barcellos LF.

PLoS Genet. 2019 Jan 17;15(1):e1007808. doi: 10.1371/journal.pgen.1007808. eCollection 2019 Jan.

6.

Vitamin D deficiency is an etiological factor for MS - No.

Langer-Gould A, Lucas RM.

Mult Scler. 2019 Apr;25(5):639-641. doi: 10.1177/1352458518808469. Epub 2018 Nov 30. No abstract available.

PMID:
30499745
7.

MS Sunshine Study: Sun Exposure But Not Vitamin D Is Associated with Multiple Sclerosis Risk in Blacks and Hispanics.

Langer-Gould A, Lucas R, Xiang AH, Chen LH, Wu J, Gonzalez E, Haraszti S, Smith JB, Quach H, Barcellos LF.

Nutrients. 2018 Feb 27;10(3). pii: E268. doi: 10.3390/nu10030268.

8.

Vitamin D-Binding Protein Polymorphisms, 25-Hydroxyvitamin D, Sunshine and Multiple Sclerosis.

Langer-Gould A, Lucas RM, Xiang AH, Wu J, Chen LH, Gonzales E, Haraszti S, Smith JB, Quach H, Barcellos LF.

Nutrients. 2018 Feb 7;10(2). pii: E184. doi: 10.3390/nu10020184.

9.

Epstein-Barr virus, cytomegalovirus, and multiple sclerosis susceptibility: A multiethnic study.

Langer-Gould A, Wu J, Lucas R, Smith J, Gonzales E, Amezcua L, Haraszti S, Chen LH, Quach H, James JA, Barcellos LF, Xiang AH.

Neurology. 2017 Sep 26;89(13):1330-1337. doi: 10.1212/WNL.0000000000004412. Epub 2017 Aug 30.

10.

Breastfeeding, ovulatory years, and risk of multiple sclerosis.

Langer-Gould A, Smith JB, Hellwig K, Gonzales E, Haraszti S, Koebnick C, Xiang A.

Neurology. 2017 Aug 8;89(6):563-569. doi: 10.1212/WNL.0000000000004207. Epub 2017 Jul 12.

11.

Perceptions of Multiple Sclerosis in Hispanic Americans: Need for Targeted Messaging.

Obiwuru O, Joseph S, Liu L, Palomeque A, Tarlow L, Langer-Gould AM, Amezcua L.

Int J MS Care. 2017 May-Jun;19(3):131-139. doi: 10.7224/1537-2073.2015-081.

12.

Oral Contraceptives and Multiple Sclerosis/Clinically Isolated Syndrome Susceptibility.

Hellwig K, Chen LH, Stancyzk FZ, Langer-Gould AM.

PLoS One. 2016 Mar 7;11(3):e0149094. doi: 10.1371/journal.pone.0149094. eCollection 2016.

13.

Breastfeeding and Disease-Modifying Therapy for Multiple Sclerosis--Reply.

Hellwig K, Langer-Gould AM.

JAMA Neurol. 2016 Apr;73(4):480-1. doi: 10.1001/jamaneurol.2015.4821. No abstract available.

PMID:
26926044
14.

Interferon-beta exposure during first trimester is safe in women with multiple sclerosis-A prospective cohort study from the German Multiple Sclerosis and Pregnancy Registry.

Thiel S, Langer-Gould A, Rockhoff M, Haghikia A, Queisser-Wahrendorf A, Gold R, Hellwig K.

Mult Scler. 2016 May;22(6):801-9. doi: 10.1177/1352458516634872. Epub 2016 Feb 26.

PMID:
26920382
15.

Glatiramer acetate during early pregnancy: A prospective cohort study.

Herbstritt S, Langer-Gould A, Rockhoff M, Haghikia A, Queisser-Wahrendorf A, Gold R, Hellwig K.

Mult Scler. 2016 May;22(6):810-6. doi: 10.1177/1352458515623366. Epub 2016 Jan 11.

PMID:
26754804
16.

Sex hormones and multiple sclerosis: another informative failure.

Langer-Gould A.

Lancet Neurol. 2016 Jan;15(1):22-3. doi: 10.1016/S1474-4422(15)00348-8. Epub 2015 Nov 25. No abstract available.

PMID:
26621681
17.

Exclusive Breastfeeding and the Effect on Postpartum Multiple Sclerosis Relapses.

Hellwig K, Rockhoff M, Herbstritt S, Borisow N, Haghikia A, Elias-Hamp B, Menck S, Gold R, Langer-Gould A.

JAMA Neurol. 2015 Oct;72(10):1132-8. doi: 10.1001/jamaneurol.2015.1806. Erratum in: JAMA Neurol. 2016 Apr;73(4):481.

PMID:
26322399
18.

Association between vaccines and neuroinflammation-reply.

Langer-Gould A.

JAMA Neurol. 2015 May;72(5):605. doi: 10.1001/jamaneurol.2015.75. No abstract available.

PMID:
25961177
19.

The pill times 2: what every woman with multiple sclerosis should know.

Henson LJ, Cavalier S, Langer-Gould AM.

Neurology. 2014 Oct 28;83(18):1685. doi: 10.1212/01.wnl.0000456505.44996.b4. No abstract available.

PMID:
25349277
20.

Vaccines and the risk of multiple sclerosis and other central nervous system demyelinating diseases.

Langer-Gould A, Qian L, Tartof SY, Brara SM, Jacobsen SJ, Beaber BE, Sy LS, Chao C, Hechter R, Tseng HF.

JAMA Neurol. 2014 Dec;71(12):1506-13. doi: 10.1001/jamaneurol.2014.2633.

PMID:
25329096
21.

Natalizumab use during the third trimester of pregnancy.

Haghikia A, Langer-Gould A, Rellensmann G, Schneider H, Tenenbaum T, Elias-Hamp B, Menck S, Zimmermann J, Herbstritt S, Marziniak M, Kümpfel T, Meinl I, Plavina T, Gold R, Hellwig K.

JAMA Neurol. 2014 Jul 1;71(7):891-5. doi: 10.1001/jamaneurol.2014.209. Review.

PMID:
24821217
22.

The incidence of clinically isolated syndrome in a multi-ethnic cohort.

Langer-Gould A, Brara SM, Beaber BE, Zhang JL.

J Neurol. 2014 Jul;261(7):1349-55. doi: 10.1007/s00415-014-7349-0. Epub 2014 Apr 29.

PMID:
24777692
23.

Association between maternal inflammatory bowel disease and adverse perinatal outcomes.

Getahun D, Fassett MJ, Longstreth GF, Koebnick C, Langer-Gould AM, Strickland D, Jacobsen SJ.

J Perinatol. 2014 Jun;34(6):435-40. doi: 10.1038/jp.2014.41. Epub 2014 Mar 20.

PMID:
24651735
24.

Immunomodulatory agents and risk of postpartum multiple sclerosis relapses.

Beaber BE, Chi MD, Brara SM, Zhang JL, Langer-Gould AM.

Perm J. 2014 Winter;18(1):9-13. doi: 10.7812/TPP/13-090.

25.

The pill times 2: what every woman with multiple sclerosis should know.

Langer-Gould AM.

Neurology. 2014 Feb 25;82(8):654-5. doi: 10.1212/WNL.0000000000000155. Epub 2014 Jan 24. No abstract available.

PMID:
24463629
26.

One can prevent post-partum MS relapses by exclusive breast feeding: yes.

Langer-Gould A, Hellwig K.

Mult Scler. 2013 Oct;19(12):1567-8. doi: 10.1177/1352458513505161. No abstract available.

PMID:
24132002
27.

The American Academy of Neurology's top five Choosing Wisely recommendations.

Mattson DH, Lisak RP, Jones DE, Corboy JR, Larson R, Gronseth G, Getchius TS, Langer-Gould A, Langer-Gould AM, Gronseth GS, Larson R, Getchius TS.

Neurology. 2013 Sep 10;81(11):1022-3. doi: 10.1212/WNL.0b013e3182a69c98. No abstract available.

PMID:
24019388
28.

Spinal cord lesions and disability in Hispanics with multiple sclerosis.

Amezcua L, Lerner A, Ledezma K, Conti D, Law M, Weiner L, Langer-Gould A.

J Neurol. 2013 Nov;260(11):2770-6. doi: 10.1007/s00415-013-7054-4. Epub 2013 Aug 3.

29.

Incidence of multiple sclerosis in multiple racial and ethnic groups.

Langer-Gould A, Brara SM, Beaber BE, Zhang JL.

Neurology. 2013 May 7;80(19):1734-9. doi: 10.1212/WNL.0b013e3182918cc2.

PMID:
23650231
30.

Reply: To PMID 22633290.

Langer-Gould AM.

J Pediatr. 2013 May;162(5):1084. doi: 10.1016/j.jpeds.2013.01.058. Epub 2013 Feb 27. No abstract available.

PMID:
23453770
31.

Effects of pregnancy and breastfeeding on the multiple sclerosis disease course.

Langer-Gould A, Beaber BE.

Clin Immunol. 2013 Nov;149(2):244-50. doi: 10.1016/j.clim.2013.01.008. Epub 2013 Jan 27. Review.

PMID:
23434027
32.

The American Academy of Neurology's top five choosing wisely recommendations.

Langer-Gould AM, Anderson WE, Armstrong MJ, Cohen AB, Eccher MA, Iverson DJ, Potrebic SB, Becker A, Larson R, Gedan A, Getchius TS, Gronseth GS.

Neurology. 2013 Sep 10;81(11):1004-11. doi: 10.1212/WNL.0b013e31828aab14. Epub 2013 Feb 20.

PMID:
23430685
33.

Childhood obesity and risk of pediatric multiple sclerosis and clinically isolated syndrome.

Langer-Gould A, Brara SM, Beaber BE, Koebnick C.

Neurology. 2013 Feb 5;80(6):548-52. doi: 10.1212/WNL.0b013e31828154f3. Epub 2013 Jan 30.

34.

Sociodemographic characteristics of members of a large, integrated health care system: comparison with US Census Bureau data.

Koebnick C, Langer-Gould AM, Gould MK, Chao CR, Iyer RL, Smith N, Chen W, Jacobsen SJ.

Perm J. 2012 Summer;16(3):37-41.

35.

Pediatric idiopathic intracranial hypertension and extreme childhood obesity.

Brara SM, Koebnick C, Porter AH, Langer-Gould A.

J Pediatr. 2012 Oct;161(4):602-7. doi: 10.1016/j.jpeds.2012.03.047. Epub 2012 May 26.

36.

Vitamin D levels in Hispanics with multiple sclerosis.

Amezcua L, Chung RH, Conti DV, Langer-Gould AM.

J Neurol. 2012 Dec;259(12):2565-70. doi: 10.1007/s00415-012-6537-z. Epub 2012 May 16.

PMID:
22588255
37.

Incidence of acquired CNS demyelinating syndromes in a multiethnic cohort of children.

Langer-Gould A, Zhang JL, Chung J, Yeung Y, Waubant E, Yao J.

Neurology. 2011 Sep 20;77(12):1143-8. doi: 10.1212/WNL.0b013e31822facdd. Epub 2011 Aug 24.

38.

Maximally tolerated versus minimally effective dose: the case of rituximab in multiple sclerosis.

Nielsen AS, Miravalle A, Langer-Gould A, Cooper J, Edwards KR, Kinkel RP.

Mult Scler. 2012 Mar;18(3):377-8. doi: 10.1177/1352458511418631. Epub 2011 Aug 9. No abstract available.

PMID:
21828201
39.

Health plan administrative records versus birth certificate records: quality of race and ethnicity information in children.

Smith N, Iyer RL, Langer-Gould A, Getahun DT, Strickland D, Jacobsen SJ, Chen W, Derose SF, Koebnick C.

BMC Health Serv Res. 2010 Nov 23;10:316. doi: 10.1186/1472-6963-10-316.

40.

Vitamin D, pregnancy, breastfeeding, and postpartum multiple sclerosis relapses.

Langer-Gould A, Huang S, Van Den Eeden SK, Gupta R, Leimpeter AD, Albers KB, Horst R, Hollis B, Steinman L, Nelson LM.

Arch Neurol. 2011 Mar;68(3):310-3. doi: 10.1001/archneurol.2010.291. Epub 2010 Nov 8.

PMID:
21059988
41.

Autoimmune diseases prior to the diagnosis of multiple sclerosis: a population-based case-control study.

Langer-Gould A, Albers KB, Van Den Eeden SK, Nelson LM.

Mult Scler. 2010 Jul;16(7):855-61. doi: 10.1177/1352458510369146. Epub 2010 May 12.

PMID:
20463037
42.

Interferon-gamma-producing T cells, pregnancy, and postpartum relapses of multiple sclerosis.

Langer-Gould A, Gupta R, Huang S, Hagan A, Atkuri K, Leimpeter AD, Albers KB, Greenwood E, Van Den Eeden SK, Steinman L, Nelson LM.

Arch Neurol. 2010 Jan;67(1):51-7. doi: 10.1001/archneurol.2009.304.

PMID:
20065129
43.

Exclusive breastfeeding and the risk of postpartum relapses in women with multiple sclerosis.

Langer-Gould A, Huang SM, Gupta R, Leimpeter AD, Greenwood E, Albers KB, Van Den Eeden SK, Nelson LM.

Arch Neurol. 2009 Aug;66(8):958-63. doi: 10.1001/archneurol.2009.132. Epub 2009 Jun 8.

PMID:
19506118
44.

Absence of neuromyelitis optica IgG antibody in an active relapsing-remitting multiple sclerosis population.

Smith CH, Waubant E, Langer-Gould A.

J Neuroophthalmol. 2009 Jun;29(2):104-6. doi: 10.1097/WNO.0b013e3181a63606.

PMID:
19491632
45.

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.

Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, Bar-Or A, Panzara M, Sarkar N, Agarwal S, Langer-Gould A, Smith CH; HERMES Trial Group.

N Engl J Med. 2008 Feb 14;358(7):676-88. doi: 10.1056/NEJMoa0706383.

46.

Clinical and demographic predictors of long-term disability in patients with relapsing-remitting multiple sclerosis: a systematic review.

Langer-Gould A, Popat RA, Huang SM, Cobb K, Fontoura P, Gould MK, Nelson LM.

Arch Neurol. 2006 Dec;63(12):1686-91. Review.

PMID:
17172607
47.

Progressive multifocal leukoencephalopathy and multiple sclerosis: lessons from natalizumab.

Langer-Gould A, Steinman L.

Curr Neurol Neurosci Rep. 2006 May;6(3):253-8. Review.

PMID:
16635435
48.

What went wrong in the natalizumab trials?

Langer-Gould A, Steinman L.

Lancet. 2006 Mar 4;367(9512):708-10. No abstract available.

PMID:
16517256
49.

Progressive multifocal leukoencephalopathy in a patient treated with natalizumab.

Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D.

N Engl J Med. 2005 Jul 28;353(4):375-81. Epub 2005 Jun 9.

50.

Strategies for managing the side effects of treatments for multiple sclerosis.

Langer-Gould A, Moses HH, Murray TJ.

Neurology. 2004 Dec 14;63(11 Suppl 5):S35-41. Review.

PMID:
15596735

Supplemental Content

Loading ...
Support Center